OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings

Rhea-AI Filing Summary

OKYO Pharma Ltd Chief Development Officer Gary S. Jacob filed an initial ownership report showing he holds 108,920 shares of common stock directly. He also reports multiple option awards over common stock with exercise prices ranging from 1.46 to 2.75 per share and expirations between 2033 and 2035.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

JACOB GARY S

(Last) (First) (Middle)

C/O OKYO PHARMA LTD,

14-15 CONDUIT STREET

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	108,920	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	03/14/2024	03/14/2033	common stock	21,154	$2.13	D
Options	03/14/2025	03/14/2033	common stock	21,154	$2.13	D
Options	03/14/2026	03/14/2033	common stock	21,154	$2.13	D
Options	03/14/2027	03/14/2033	common stock	21,154	$2.13	D
Options	03/13/2025	03/13/2034	common stock	16,666	$1.46	D
Options	03/13/2025	03/13/2034	common stock	16,666	$1.46	D
Options	03/13/2025	03/13/2034	common stock	16,667	$1.46	D
Options	01/29/2026	01/29/2035	common stock	102,653	$1.6	D
Options	01/29/2027	01/29/2035	common stock	102,653	$1.6	D
Options	01/29/2028	01/29/2035	common stock	102,564	$1.6	D
Options	03/25/2026	03/25/2035	common stock	50,000	$1.5	D
Options	03/25/2027	03/25/2035	common stock	50,000	$1.5	D
Options	03/25/2028	03/25/2035	common stock	50,000	$1.5	D
Options	03/25/2029	03/25/2035	common stock	50,000	$1.5	D
Options	07/16/2026	07/16/2035	common stock	89,356	$2.75	D
Options	07/16/2027	07/16/2035	common stock	89,356	$2.75	D
Options	07/16/2028	07/16/2035	common stock	89,356	$2.75	D
Options	07/16/2029	07/16/2035	common stock	89,356	$2.75	D

Explanation of Responses:

	/s/ Gary Jacob	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the OKYO Pharma (OKYO) Form 3 filed by Gary S. Jacob show?

The Form 3 shows Gary S. Jacob, Chief Development Officer of OKYO Pharma, reporting initial beneficial ownership. He directly holds 108,920 common shares and multiple option positions over common stock at various exercise prices and expirations through 2035.

How many OKYO Pharma common shares does Gary S. Jacob report on Form 3?

Gary S. Jacob reports direct ownership of 108,920 OKYO Pharma common shares. This position is disclosed as part of his initial beneficial ownership statement as Chief Development Officer, alongside several option holdings over additional common stock.

What stock options over OKYO Pharma shares does Gary S. Jacob report holding?

He reports several option positions over OKYO Pharma common stock with exercise prices around $1.46, $1.50, $1.60, $2.13 and $2.75 per share, and expiration dates spanning from 2033 to 2035, all held as direct ownership.

Does the OKYO Pharma (OKYO) Form 3 show any recent insider buying or selling?

The Form 3 lists holdings only and shows no reported insider purchases or sales. Transactions are classified as holdings with unknown transaction codes and a neutral net buy/sell direction in the transaction summary.

What role does Gary S. Jacob hold at OKYO Pharma in this Form 3?

In this Form 3, Gary S. Jacob is identified as both a director and an officer of OKYO Pharma, serving as Chief Development Officer, and he reports his direct holdings of common stock and options over common stock.